The round was led by Genome BC and Boardwalk Ventures Inc. and includes funding from Tower Beach Capital Ltd., Coleco Investments, and Quimby Investments (VCC) Ltd.
The company intends to use the funds to bring its test to the US market.
Led by William Dubiel, President and CEO, LightIntegra Technology has advanced ThromboLUX, a non-invasive, rapid optical test that assesses platelet activation status, which does not require dilution. As a routine test for platelet concentrates, it identifies which platelet units may be best suited for prophylaxis and which units may be best suited for therapeutic use.
The medical diagnostics company launched from the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer.
Source. FinSMEs, Staff, April 24, 2019
***
This post was brought to you by Woewoda Communications, your partner in the Canadian private equity and startup markets; offering strategic communications, public relations & investor relation services to Canadian VCs, PEs, Angels, Endowments/Trusts, Family Offices, and Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.
Are you a Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience.
Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa, and Halifax.
No comments:
Post a Comment